Published in Eur J Pediatr on April 03, 2009
Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev (2010) 9.82
A new strategy to fight antimicrobial resistance: the revival of old antibiotics. Front Microbiol (2014) 0.94
Incidence, characteristics, and outcomes of patients with bone and joint infections due to community-associated methicillin-resistant Staphylococcus aureus: a systematic review. Eur J Clin Microbiol Infect Dis (2013) 0.91
Primary pyomyositis: an unusual presentation in an older patient with no recognised risk factors. BMJ Case Rep (2012) 0.78
Life-threatening MRSA sepsis with bilateral pneumonia, osteomyelitis, and septic arthritis of the knee in a previously healthy 13-year-old boy: a case report. Acta Radiol Open (2016) 0.75
Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis (1999) 19.52
Multiplex PCR strategy for rapid identification of structural types and variants of the mec element in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2002) 15.11
Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. Clin Microbiol Rev (1997) 6.98
Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect Dis (2005) 6.85
Community-acquired methicillin-resistant Staphylococcus aureus infections in France: emergence of a single clone that produces Panton-Valentine leukocidin. Clin Infect Dis (2002) 5.75
Severe Staphylococcal sepsis in adolescents in the era of community-acquired methicillin-resistant Staphylococcus aureus. Pediatrics (2005) 3.13
Bacteremia caused by staphylococci with inducible vancomycin heteroresistance. Clin Infect Dis (1999) 3.11
Staphylococcus aureus isolates carrying Panton-Valentine leucocidin genes in England and Wales: frequency, characterization, and association with clinical disease. J Clin Microbiol (2005) 2.95
Community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus musculoskeletal infections in children. Pediatr Infect Dis J (2004) 2.91
Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children. N Engl J Med (2005) 2.91
Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother (2006) 2.82
Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza--Louisiana and Georgia, December 2006-January 2007. MMWR Morb Mortal Wkly Rep (2007) 2.20
Emergence of community-associated methicillin resistant Staphylococcus aureus in Hawaii, 2001-2003. J Infect (2006) 1.98
Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J (2003) 1.76
Methicillin-resistant Staphylococcus aureus in the Australian community: an evolving epidemic. Med J Aust (2006) 1.73
Emergence of community-acquired methicillin-resistant Staphylococcus aureus (MRSA) infection in Queensland, Australia. Int J Infect Dis (2003) 1.68
[Fatal pneumonia in an adolescent due to community-acquired methicillin-resistant Staphylococcus aureus positive for Panton-Valentine-leukocidin]. Ned Tijdschr Geneeskd (2003) 1.68
Variability among pediatric infectious diseases specialists in the treatment and prevention of methicillin-resistant Staphylococcus aureus skin and soft tissue infections. Pediatr Infect Dis J (2008) 1.39
Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother (2005) 1.26
Daptomycin therapy for invasive Gram-positive bacterial infections in children. Pediatr Infect Dis J (2007) 1.20
Carriage of methicillin-resistant Staphylococcus aureus in a Queensland Indigenous community. Med J Aust (2006) 1.10
Community-acquired methicillin-resistant Staphylococcus aureus causes severe disseminated infection and deep venous thrombosis in children: literature review and recommendations for management. J Paediatr Child Health (2007) 1.08
Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan. J Antimicrob Chemother (2007) 1.05
Methicillin-resistant Staphylococcus aureus producing Panton-Valentine leukocidin as a cause of acute osteomyelitis in children. Clin Microbiol Infect (2007) 0.90
Clinical and molecular epidemiology of community-acquired, methicillin-resistant Staphylococcus aureus infections in children in central Greece. Eur J Clin Microbiol Infect Dis (2008) 0.85
Pediatric community-acquired methicillin-resistant Staphylococcus aureus infection and colonization: trends and management. Curr Opin Pediatr (2007) 0.84
Epidemiology of methicillin-resistant Staphylococcus aureus at a pediatric healthcare system, 1991-2003. Pediatr Infect Dis J (2007) 0.84
What would pediatric infectious disease consultants recommend for management of culture-negative acute hematogenous osteomyelitis? J Pediatr Orthop (2007) 0.82
Fatal sepsis and necrotizing pneumonia in a child due to community-acquired methicillin-resistant Staphylococcus aureus: case report and literature review. Scand J Infect Dis (2005) 0.81
The treatment of community-acquired methicillin-resistant Staphylococcus aureus infections. Pediatr Infect Dis J (2008) 0.81
Cutaneous community-associated methicillin-resistant staphylococcus aureus among all skin and soft-tissue infections in two geographically distant pediatric emergency departments. Acad Emerg Med (2006) 0.81
Community-acquired disseminated methicillin-resistant Staphylococcus aureus infection: case report and clinical implications. Ann Trop Paediatr (2005) 0.79
Recent appearance of clindamycin resistance in community-acquired methicillin-resistant Staphylococcus aureus (MRSA) in south-east Queensland. Med J Aust (2002) 0.79
Community associated MRSA: an alert to paediatricians. Arch Dis Child (2006) 0.78
Linezolid versus vancomycin for prosthetic joint infections: a cost analysis. Infection (2007) 0.76
Healthy children with invasive community-acquired methicillin-resistant Staphylococcus aureus infections. Pediatr Emerg Care (2006) 0.76
More challenges in the prevention and management of community-associated, methicillin-resistant Staphylococcus aureus skin disease. Ann Intern Med (2008) 0.75
Staphylococcus aureus: a guide for the perplexed. Med J Aust (2006) 0.75
Emergency department management of community-acquired methicillin-resistant Staphylococcus aureus. Pediatr Emerg Care (2008) 0.75
Linezolid in children: recent patents and advances. Recent Pat Antiinfect Drug Discov (2007) 0.75
Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis (2012) 5.66
Infections caused by Scedosporium spp. Clin Microbiol Rev (2008) 2.69
Zygomycosis in children: a systematic review and analysis of reported cases. Pediatr Infect Dis J (2007) 2.25
Clonal spread of KPC-2 carbapenemase-producing Klebsiella pneumoniae strains in Greece. J Antimicrob Chemother (2009) 1.97
Colistin administration to pediatric and neonatal patients. Eur J Pediatr (2010) 1.83
Central nervous system aspergillosis in children: a systematic review of reported cases. Int J Infect Dis (2007) 1.75
Parapneumonic pleural effusions caused by Streptococcus pneumoniae serotype 3 in children immunized with 13-valent conjugated pneumococcal vaccine. Pediatr Infect Dis J (2014) 1.75
A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. Intensive Care Med (2013) 1.74
Bloodstream infections caused by metallo-β-lactamase/Klebsiella pneumoniae carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes. Infect Control Hosp Epidemiol (2010) 1.55
Combination therapy for mucormycosis: why, what, and how? Clin Infect Dis (2012) 1.41
Immune haemolytic anaemia due to visceral leishmaniasis in a young child. Eur J Pediatr (2003) 1.39
Fungal infections in primary immunodeficiencies. Eur J Pediatr (2007) 1.37
Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms. Antimicrob Agents Chemother (2007) 1.36
Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. Antimicrob Agents Chemother (2007) 1.31
Host-dependent patterns of tissue injury in invasive pulmonary aspergillosis. Am J Clin Pathol (2007) 1.29
Rhino-orbital-cerebral mucormycosis. Curr Infect Dis Rep (2012) 1.29
Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillus fumigatus. Antimicrob Agents Chemother (2009) 1.29
Generation of highly purified and functionally active human TH1 cells against Aspergillus fumigatus. Blood (2005) 1.28
Fungemia due to Trichosporon asahii in a neutropenic child refractory to amphotericin B: clearance with voriconazole. J Pediatr Hematol Oncol (2005) 1.26
Expression of genes encoding innate host defense molecules in normal human monocytes in response to Candida albicans. Infect Immun (2005) 1.24
Functional genomics of innate host defense molecules in normal human monocytes in response to Aspergillus fumigatus. Infect Immun (2006) 1.24
Candida osteomyelitis: analysis of 207 pediatric and adult cases (1970-2011). Clin Infect Dis (2012) 1.22
Interferon- gamma and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. J Infect Dis (2005) 1.18
Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species. Antimicrob Agents Chemother (2006) 1.16
Osteomyelitis due to Aspergillus spp. in patients with chronic granulomatous disease: comparison of Aspergillus nidulans and Aspergillus fumigatus. Int J Infect Dis (2004) 1.13
Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates. Pediatr Infect Dis J (2012) 1.09
Differential correlation between rates of antimicrobial drug consumption and prevalence of antimicrobial resistance in a tertiary care hospital in Greece. Infect Control Hosp Epidemiol (2008) 1.08
Tumor markers in biological fluids associated with pregnancy. Crit Rev Clin Lab Sci (2007) 1.05
The influence of the mode of delivery on circulating cytokine concentrations in the perinatal period. Early Hum Dev (2004) 1.05
How does antifungal pharmacology differ for mucormycosis versus aspergillosis? Clin Infect Dis (2012) 1.05
Interactions between human phagocytes and Candida albicans biofilms alone and in combination with antifungal agents. J Infect Dis (2010) 1.05
Successful treatment of multidrug-resistant Acinetobacter baumannii central nervous system infections with colistin. J Clin Microbiol (2005) 1.02
Antifungal triazoles and polymorphonuclear leukocytes synergize to cause increased hyphal damage to Scedosporium prolificans and Scedosporium apiospermum. Antimicrob Agents Chemother (2002) 1.01
Scedosporium apiospermum infection after near-drowning. Mycoses (2007) 1.01
Comparative study of quantitative ultrasonography and dual-energy X-ray absorptiometry for evaluating renal osteodystrophy in children with chronic kidney disease. J Bone Miner Metab (2010) 1.01
Invasive candidiasis in pediatric intensive care patients: epidemiology, risk factors, management, and outcome. Intensive Care Med (2007) 0.99
Use of high inoculum for early metabolic signalling and rapid susceptibility testing of Aspergillus species. J Antimicrob Chemother (2006) 0.98
Epidemiology, risk factors and outcome of Candida parapsilosis bloodstream infection in children. Pediatr Infect Dis J (2012) 0.97
Micafungin: pharmacology, experimental therapeutics and clinical applications. Expert Opin Investig Drugs (2005) 0.96
Use of ciprofloxacin in neonatal sepsis: lack of adverse effects up to one year. Pediatr Infect Dis J (2004) 0.95
Interaction of amphotericin B lipid formulations and triazoles with human polymorphonuclear leucocytes for antifungal activity against Zygomycetes. Mycoses (2008) 0.95
Future directions in mucormycosis research. Clin Infect Dis (2012) 0.95
Molecular epidemiology of outbreak-related pseudomonas aeruginosa strains carrying the novel variant blaVIM-17 metallo-beta-lactamase gene. Antimicrob Agents Chemother (2009) 0.95
Rapid susceptibility testing of medically important zygomycetes by XTT assay. J Clin Microbiol (2006) 0.95
Differential fungicidal activities of amphotericin B and voriconazole against Aspergillus species determined by microbroth methodology. Antimicrob Agents Chemother (2007) 0.95
Immunomodulatory effects of voriconazole on monocytes challenged with Aspergillus fumigatus: differential role of Toll-like receptors. Antimicrob Agents Chemother (2008) 0.94
Minireview: host defence in invasive aspergillosis. Mycoses (2013) 0.93
Posaconazole: when and how? The clinician's view. Mycoses (2011) 0.93
Outcome of urinary tract infections caused by extended spectrum β-lactamase-producing Enterobacteriaceae in children. Pediatr Infect Dis J (2011) 0.93
Non-Aspergillus fungal infections in chronic granulomatous disease. Mycoses (2013) 0.92
Daptomycin use in a neonate: serum level monitoring and outcome. Am J Perinatol (2009) 0.91
Acquisition of imipenem-resistant Acinetobacter baumannii in a pediatric intensive care unit: A case-control study. Intensive Care Med (2006) 0.91
Treatment and timing in invasive mould disease. J Antimicrob Chemother (2011) 0.90
Use of linezolid in pediatrics: a critical review. Int J Infect Dis (2010) 0.90
Risk factors for nasopharyngeal carriage of drug-resistant Streptococcus pneumoniae: data from a nation-wide surveillance study in Greece. BMC Infect Dis (2009) 0.89
Serum and cerebrospinal fluid levels of colistin in pediatric patients. Antimicrob Agents Chemother (2010) 0.88
Amphotericin B lipid complex exerts additive antifungal activity in combination with polymorphonuclear leucocytes against Scedosporium prolificans and Scedosporium apiospermum. J Antimicrob Chemother (2002) 0.88
Activities of triazole-echinocandin combinations against Candida species in biofilms and as planktonic cells. Antimicrob Agents Chemother (2011) 0.88
What can we learn and what do we need to know amidst the iatrogenic outbreak of Exserohilum rostratum meningitis? Clin Infect Dis (2013) 0.88
Vancomycin-resistant Enterococcus outbreak in a neonatal intensive care unit: epidemiology, molecular analysis and risk factors. Am J Infect Control (2013) 0.88
Outbreak of bloodstream infections because of Serratia marcescens in a pediatric department. Am J Infect Control (2012) 0.87
Filamentous fungi in a tertiary care hospital: environmental surveillance and susceptibility to antifungal drugs. Infect Control Hosp Epidemiol (2006) 0.87
Seroepidemiological study of pandemic influenza H1N1 following the 2009-2010 wave in Greece. Vaccine (2011) 0.87
Additive antifungal activity of anidulafungin and human neutrophils against Candida parapsilosis biofilms. J Antimicrob Chemother (2010) 0.86
Fungal colonization in the neonatal intensive care unit: risk factors, drug susceptibility, and association with invasive fungal infections. Am J Perinatol (2007) 0.86
Isobolographic analysis of pharmacodynamic interactions between antifungal agents and ciprofloxacin against Candida albicans and Aspergillus fumigatus. Antimicrob Agents Chemother (2008) 0.86
Inteferon gamma and granulocyte-macrophage colony-stimulating factor augment the antifungal activity of human polymorphonuclear leukocytes against Scedosporium spp.: comparison with Aspergillus spp. Med Mycol (2005) 0.85
Advances in antibacterial therapy against emerging bacterial pathogens. Semin Hematol (2009) 0.85
Congenital brucellosis: a rare cause of respiratory distress in neonates. Am J Perinatol (2007) 0.84
Therapeutic strategies for invasive fungal infections in neonatal and pediatric patients. Expert Opin Pharmacother (2008) 0.84
Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother (2011) 0.84
Current management of late onset neonatal bacterial sepsis in five European countries. Eur J Pediatr (2014) 0.84
Relationship between metabolism and biomass of medically important zygomycetes. Med Mycol (2006) 0.84
Frequency, clinical characteristics, and genotype distribution of rotavirus gastroenteritis in Greece (2007-2008). J Med Virol (2011) 0.83
Human phagocytic cell responses to Scedosporium apiospermum (Pseudallescheria boydii): variable susceptibility to oxidative injury. Infect Immun (2003) 0.82
Trichosporon asahii: an unusual cause of invasive infection in neonates. Pediatr Infect Dis J (2002) 0.82
Primary intestinal lymphangiectasia: is it always bad? Two cases with different outcome. Case Rep Gastroenterol (2013) 0.82
Bilirubin levels predict renal cortical changes in jaundiced neonates with urinary tract infection. World J Pediatr (2009) 0.82
Comparative pharmacodynamic interaction analysis between ciprofloxacin, moxifloxacin and levofloxacin and antifungal agents against Candida albicans and Aspergillus fumigatus. J Antimicrob Chemother (2008) 0.82
Exserohilum infections: review of 48 cases before the 2012 United States outbreak. Med Mycol (2014) 0.82
Selective effects of interleukin (IL)-15 on antifungal activity and IL-8 release by polymorphonuclear leukocytes in response to hyphae of Aspergillus species. J Infect Dis (2003) 0.82
Indicative markers of cell proliferation and apoptosis during the perinatal period. Am J Perinatol (2003) 0.82
Species-specific and drug-specific differences in susceptibility of Candida biofilms to echinocandins: characterization of less common bloodstream isolates. Antimicrob Agents Chemother (2013) 0.82
Pneumocystis pneumonia in children. Paediatr Respir Rev (2009) 0.81
Micafungin in premature and non-premature infants: a systematic review of 9 clinical trials. Pediatr Infect Dis J (2014) 0.81
Fungal biomass is a key factor affecting polymorphonuclear leucocyte-induced hyphal damage of filamentous fungi. Mycoses (2009) 0.81
Differential transcriptional profiles induced by amphotericin B formulations on human monocytes during response to hyphae of Aspergillus fumigatus. Med Mycol (2010) 0.80
Amphotericin B formulations variably enhance antifungal activity of human neutrophils and monocytes against Fusarium solani: comparison with Aspergillus fumigatus. J Antimicrob Chemother (2008) 0.80
Antibiotics-induced acute interstitial nephritis in 6 children. Urol Int (2006) 0.80
Risk of azole-enhanced vincristine neurotoxicity in pediatric patients with hematological malignancies: old problem - new dilemma. Pediatr Blood Cancer (2011) 0.80
Moyamoya syndrome and neurofibromatosis type 1. Ital J Pediatr (2014) 0.80
Osteomyelitis due to Aspergillus species in chronic granulomatous disease: an update of the literature. Mycoses (2011) 0.80
Diagnostic imaging of experimental invasive pulmonary aspergillosis. Med Mycol (2009) 0.79
Brain abscesses resulting from Bacillus cereus and an Aspergillus-like mold. J Pediatr Hematol Oncol (2002) 0.79
Post‒cataract surgery endophthalmitis outbreak caused by multidrug-resistant Pseudomonas aeruginosa. Am J Infect Control (2011) 0.79
Cytokine concentrations during the first days of life. Eur J Obstet Gynecol Reprod Biol (2006) 0.79